Clinical trials: Hematologic Malignancy
Hodgkin's Disease, Leukemia
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
The purpose of this study is to determine if we can prevent Epstein Barr Virus lymphomas by the monthly administration of an (antibody) protein against B lymphocytes called Rituximab.
- Conditions
- Hodgkin's Disease, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT00648037
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Waldenstrom's Macroglobulinemia
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
This research study is evaluating a drug called ixazomib (also known as MLN9708) in combination with dexamethasone and rituximab (the regimen is called IDR) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).
- Trial name
- NCT02400437
- Testing
- Ixazomib, Dexamethasone, Rituximab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying how well rituximab works in preventing acute graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for hematologic cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT01044745
- Testing
- rituximab, mycophenolate mofetil, tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Acute Myeloid Leukemia
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
The primary objective of the trial is to compare the two-year relapse-free survival (RFS) of patients with acute myeloid leukemia (AML), presumed to be at high risk for relapse due to the presence of leukemia stem cells (LSCs) in…
- Trial name
- NCT01588951
- Testing
- Cytarabine consolidation, Allogeneic transplant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myeloid Leukemia
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
This Phase Ib study is designed to evaluate the safety and pharmacokinetics of atezolizumab when given in combination with Hu5F9-G4 to patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
- Trial name
- NCT03922477
- Testing
- Atezolizumab, Hu5F9-G4
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)
One of the complications that can occur after a stem cell transplant is called graft versus host disease (GVHD). Another complication is that multiple myeloma may come back (relapse).
- Trial name
- NCT01303965
- Testing
- Sirolimus, Tacrolimus, Lenalidomide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sherif S. Farag
Waldenstrom's Macroglobulinemia
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 90% of the patients with Waldenström's macroglobulinemia.
- Trial name
- 8400-401 (NCT02092909)
- Testing
- IMO-8400
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
The purpose of the study is to determine if participants who receive the GVHD prophylaxis medication pentostatin will have less severe hepatic toxicities than those receiving MTX.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Hodgkin's Disease
- Trial name
- NCT01188798
- Testing
- Methotrexate, Pentostatin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- St. Jude Children's Research Hospital
Hematologic Diseases, Hematologic Malignancies
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
The major purpose of this study is to evaluate the curative potential of white cell growth hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants.
- Trial name
- NCT00231309
- Testing
- Granulocyte Colony Stimulating Factor
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Emory University
Multiple Myeloma
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
- Trial name
- CARTITUDE-4 (NCT04181827)
- Testing
- Cilta-cel, Pomalidomide, Bortezomib
- Where
- 88 sites in United States, Australia and 14 more
- Volunteers
- 419 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to…
- Trial name
- NCT00651261
- Testing
- cytarabine, daunorubicin, midostaurin
- Where
- 176 sites in United States, Canada
- Volunteers
- 717 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7)
CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase 2 clinical trial studies how well CPX-351 (liposomal cytarabine-daunorubicin) works in treating patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
- Conditions
- Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)
- Trial name
- NCT02019069
- Testing
- liposomal cytarabine-daunorubicin CPX-351
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Rondeep Brar
Multiple Myeloma, Refractory Multiple Myeloma
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or…
- Conditions
- Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
- Trial name
- NCT04302324
- Testing
- Daratumumab SC, Clarithromycin, Pomalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
This is a multi-center, open-label, single arm, non-comparative phase II trial, designed to evaluate the efficacy of plitidepsin in combination with bortezomib and dexamethasone in patients with Multiple Myeloma (MM) double…
- Trial name
- NCT03117361
- Testing
- plitidepsin, Bortezomib, Dexamethasone
- Where
- 13 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- PharmaMar
Multiple Myeloma and Plasma Cell Neoplasm
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00558896
- Testing
- dexamethasone, pomalidomide
- Where
- 3 sites in United States
- Volunteers
- 378 people
- Sponsor
- Mayo Clinic
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL)
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin…
- Conditions
- Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL)
- Trial name
- NCT01994382
- Testing
- Cerdulatinib, Rituximab
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells.
- Trial name
- NCT00445484
- Testing
- pneumococcal polyvalent vaccine, lenalidomide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myelogenous Leukemia
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
The purpose of this study is to establish the maximum tolerated dose (MTD), and to assess the safety and tolerability of MLN4924 (pevonedistat) in combination with azacitidine in treatment naive participants with AML who were 60…
- Trial name
- NCT01814826
- Testing
- MLN4924, Azacitidine
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Tumors
Study of BMS-986158 in Subjects With Select Advanced Cancers
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
- Trial name
- BET (NCT02419417)
- Testing
- BMS-986158, Nivolumab
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 83 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Myeloid, Acute
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse
Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. In addition, acute myeloid leukemia patients who are in complete remission with high risk to relapse…
- Trial name
- NCT01690624
- Testing
- BI 836858
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.